Dr. Hixson currently serves as the Chairman of the Board of Directors. Prior to that, Harry served both as the Chief Executive Officer and the Chairman of the Board of Directors from 2003 to 2014. Before Sequenom, Hixson served on the Board of Directors of BrainCells, Inc., a biopharmaceutical company focused on central nervous system drug development, where he was Chief Executive Officer from July 2004 until September 2005. Dr. Hixson served as Chief Executive Officer of Elitra Pharmaceuticals, Inc., a biopharmaceutical company focused on anti-infective drug development, from February 1998 until May 2003. He served as President and Chief Operating Officer of Amgen Inc., and was a member of its board of directors from 1988 to 1991. Prior to Amgen, Dr. Hixson held various management positions with Abbott Laboratories, including Vice President, Diagnostic Products Business Group, and Vice President, Research and Development in the Diagnostics Division. Dr. Hixson also is a director of Arena Pharmaceuticals, Inc. Dr. Hixson received his PhD in physical biochemistry from Purdue University and an MBA from the University of Chicago.